Basilea Announces FDA Acceptance of New Drug Application for Antibiotic Ceftobiprole
Seeking approval for Staphylococcus aureus bacteremia (SAB), acute bacterial skin and skin structure infections (ABSSSI), and community-acquired bacterial pneumonia (CABP)
Prescription Drug User Fee Act (PDUFA) goal date set for April 03,...
Source: Drugs.com - New Drug Applications - Category: Drugs & Pharmacology Source Type: news
More News: Bacterial Pneumonia | Drugs & Pharmacology | New Drug Applications | Pneumonia | Skin | Staphylococcus Aureus